Nevertheless, given the importance of microenvironment, especially angiogenesis, in the prognosis of glioblastoma treatment, future immunotherapy against CD47 or CD24 should include the quantitative evaluations of hemodynamic changes within and surrounding the glioblastoma. The gene discussed is CD24; the disease is glioblastoma.